Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer

鸟氨酸脱羧酶在细胞增殖和癌症中的调节和作用

• 批准号: 7991376
• 负责人: John L. Cleveland
• 金额: $ 41.73万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-03-04 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7991376
• 关键词: Address; Affect; Anabolism; Apoptosis; B lymphoid malignancy; B-Cell Lymphomas; B-Lymphocytes; Binding; Boxing; Breast Adenocarcinoma; Carcinogens; Cell Cycle Arrest; Cell Proliferation; Cell division; Cells; Chemoprevention; Clinic; Clinical Trials; Colon Carcinoma; Complex; Cyclin-Dependent Kinase Inhibitor; DL-alpha-Difluoromethylornithine; Data; Development; Dimerization; Dose; Down-Regulation; Early Diagnosis; Enzymes; Family; Funding; Genes; Genetic; Genetic Transcription; Genome; Goals; Health; Homeostasis; Human; Knockout Mice; Lead; Letters; Longevity; Lung Adenocarcinoma; Lymphoma; Lymphomagenesis; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Mediating; Mediator of activation protein; Metabolic; Metabolism; Mission; Modeling; Mus; Mutate; Mutation; Nature; Neuroblastoma; Normal Cell; Oncogene Proteins; Oncogenes; Oncogenic; Ornithine Decarboxylase; Papilloma; Pathway interactions; Play; Polyamines; Premalignant; Protein p53; Proteins; Putrescine; Refractory; Regulation; Research Support; Resistance; Role; S Phase; Signal Transduction; Skin Neoplasms; Tamoxifen; Testing; Therapeutic Index; Therapy Clinical Trials; Transgenic Mice; Tumor Suppressor Proteins; addiction; base; cancer cell; cancer chemoprevention; cancer prevention; cancer therapy; carcinogenesis; cell growth; clinically relevant; cyclin-dependent kinase inhibitor 1B; expectation; inhibitor/antagonist; loss of function mutation; malignant breast neoplasm; malignant state; mouse model; multicatalytic endopeptidase complex; mutant; neoplastic cell; outcome forecast; prevent; programs; protein expression; ras Oncogene; response; suicide inhibitor; transcription factor; tumor; tumorigenesis; ubiquitin-protein ligase

DESCRIPTION (provided by applicant): The Myc family of oncogenic transcription factors is activated in ~70% of human cancers and they regulate the transcription of a large cast (10-15%) of the genome to coordinate metabolism, cell growth and division, differentiation, and development. Further, Myc lies downstream of activated Ras oncoproteins that are frequently mutated in human cancers, where Ras signaling impairs turnover of Myc protein and augments its transcriptional activity. Over the past funding cycle we demonstrated that Myc's proliferative response is rate limiting for tumor development. Remarkably, this pathway strictly relies on a single Myc transcription target, ornithine decarboxylase (Odc), the rate limiting enzyme of polyamine biosynthesis. Here we demonstrated that treatment with the Odc suicide inhibitor DFMO, or simply halving the levels of Odc (in Odc+/- mice), triples the lifespan of tumor-prone, Myc transgenic mice and that it also impairs epidermal carcinogenesis, which is associated with activating mutations in Ras. Collectively, these findings suggest that targeting Odc will have widespread benefit in cancer prevention, a fact now validated in ongoing human cancer chemoprevention trials. Further, we established that targeting Odc disables Myc's proliferative response by selectively affecting Myc's ability to provoke the degradation of the cyclin- dependent kinase inhibitor p27Kip1, a tumor suppressor that inhibits entry and progression through S-phase. Here we first demonstrated that Myc triggers p27Kip1 degradation by activating the transcription of Cks1, a component of the SCFSkp2 E3 ubiquitin ligase complex that directs p27Kip1 destruction. Surprisingly, we have now shown that Odc is required for Myc to induce Cks1 transcription. Collectively, these findings suggest a Myc>Odc>Cks1-to-p27Kip1 pathway drives Myc-induced proliferation and tumorigenesis. Using validated Myc-driven mouse models of B cell lymphoma and mammary adenocarcinoma, and of K-Ras-directed lung adenocarcinoma, we will test the roles of Odc in oncogene-driven proliferation and tumor development, the maintenance of the malignant state, and its interplay with tumor suppressor pathways. These studies include those that evaluate potential therapeutic index, where the intrinsic effects of Odc loss on pre- existing tumor cells versus its effects in normal cells will be determined. We will also critically assess the roles of p27Kip1 and Cks1 as downstream targets of Odc in cancer development and tumor maintenance, and will define the mechanism by which Odc regulates Cks1 and p27Kip1 expression. Given the pervasive and aggressive nature of Myc- and Ras-associated malignancies in human cancer, especially in the three malignancies interrogated herein, and clinical trials establishing the efficacy of targeting Odc in human cancer chemoprevention, the proposed studies are clearly highly relevant to the mission of the NCI. PUBLIC HEALTH RELEVANCE: The research supported by this revised, competitive renewal application (R01 CA100603A1) is directly, clinically relevant to chemoprevention and perhaps therapy for three refractory, devastating human malignancies, lymphoma, breast cancer, and lung adenocarcinoma. Our studies have focused on the clinically validated target ornithine decarboxylase (Odc), a metabolic enzyme whose expression is directly induced by Myc oncoproteins, and also by mutated Ras oncogenes, which together are activated in >75% of human tumors. Importantly, we have shown that targeting Odc impairs Myc's proliferative response and triples the lifespan of tumor-prone, Myc transgenic mice, and that this also compromises the development of skin tumors having Ras oncogene involvement. The proposed studies will define the roles of Odc in regulating the development and maintenance of lymphoma and lung and breast cancer, and will resolve how Odc regulates the proliferative response provoked by oncogenes, with the expectation that these studies will reveal new targets for cancer prevention and treatment.

描述（由申请人提供）：Myc家族的致癌转录因子在约70%的人类癌症中被激活，它们调节大量（10-15%）基因组的转录，以协调代谢、细胞生长和分裂、分化和发育。此外，Myc位于活化的Ras癌蛋白的下游，Ras癌蛋白在人类癌症中经常发生突变，其中Ras信号会损害Myc蛋白的周转并增强其转录活性。在过去的资助周期中，我们证明了Myc的增殖反应限制了肿瘤的发展。值得注意的是，该途径严格依赖于一个单一的Myc转录靶点，鸟氨酸脱羧酶（Odc），多胺生物合成的限速酶。在这里，我们证明了用Odc自杀抑制剂DFMO治疗，或简单地将Odc水平减半（在Odc+/-小鼠中），可使易患肿瘤的Myc转基因小鼠的寿命延长三倍，并且它还会损害表皮癌的发生，这与Ras的激活突变有关。总的来说，这些发现表明，针对Odc将在癌症预防方面具有广泛的益处，这一事实目前正在进行的人类癌症化学预防试验中得到验证。此外，我们确定靶向Odc通过选择性地影响Myc刺激细胞周期蛋白依赖性激酶抑制剂p27Kip1降解的能力来禁用Myc的增殖反应，p27Kip1是一种抑制s期进入和进展的肿瘤抑制因子。在这里，我们首先证明了Myc通过激活Cks1的转录来触发p27Kip1的降解，Cks1是SCFSkp2 E3泛素连接酶复合物的一个组成部分，指导p27Kip1的破坏。令人惊讶的是，我们现在已经证明，Odc是Myc诱导Cks1转录所必需的。总之，这些发现表明Myc>Odc>Cks1-to-p27Kip1通路驱动Myc诱导的增殖和肿瘤发生。通过验证myc驱动的B细胞淋巴瘤和乳腺腺癌小鼠模型，以及k - ras导向的肺腺癌，我们将测试Odc在癌基因驱动的增殖和肿瘤发展、恶性状态的维持及其与肿瘤抑制通路的相互作用中的作用。这些研究包括那些评估潜在治疗指标的研究，在这些研究中，将确定Odc损失对预先存在的肿瘤细胞的内在影响与其对正常细胞的影响。我们还将严格评估p27Kip1和Cks1作为Odc在癌症发展和肿瘤维持中的下游靶点的作用，并将确定Odc调节Cks1和p27Kip1表达的机制。鉴于Myc-和ras -相关恶性肿瘤在人类癌症中的普遍和侵袭性，特别是在本文所讨论的三种恶性肿瘤中，以及临床试验确定靶向Odc在人类癌症化学预防中的有效性，拟议的研究显然与NCI的使命高度相关。公共卫生相关性：这项修订后的竞争性续期申请（R01 CA100603A1）支持的研究与三种难治性、破坏性人类恶性肿瘤（淋巴瘤、乳腺癌和肺腺癌）的化学预防和治疗直接、临床相关。我们的研究集中在临床验证的靶鸟氨酸脱羧酶（Odc）上，这是一种代谢酶，其表达直接由Myc癌蛋白和突变的Ras癌基因诱导，它们在75%的人类肿瘤中被激活。重要的是，我们已经证明，靶向Odc会损害Myc的增殖反应，并使肿瘤易发的Myc转基因小鼠的寿命延长三倍，而且这也会损害Ras癌基因参与的皮肤肿瘤的发展。拟开展的研究将明确Odc在调节淋巴瘤、肺癌和乳腺癌的发展和维持中的作用，并将解决Odc如何调节癌基因引发的增殖反应，期望这些研究将揭示癌症预防和治疗的新靶点。